Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lemborexant for the Treatment of Residual Insomnia in Adequately Treated Major Depressive Disorder: A Pilot Randomized Controlled Trial

NCT06843187 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT06843187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lemborexant for the Treatment of Residual Insomnia in Adequately Treated Major Depressive Disorder: A Pilot Randomized Controlled Trial
Lead sponsor
Unity Health Toronto
Phase
Phase 2
Overall status
Terminated
Start date
September 25, 2024
Completion date
July 15, 2026
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia comorbid to psychiatric disorder, major depressive disorder(mdd)